RD Saúde (B3: RADL3) revenue
RD Saúde reported revenue of BRL 44,250m for fiscal 2025, 13.8% more than in fiscal 2024 (BRL 38,872m). Since fiscal 2016 its revenue has grown by 293.1%, an average growth of 16.4% a year.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | BRL 44,250m | +13.8% | BRL 2,744m | 6.2% |
| 2024 | BRL 38,872m | +14.4% | BRL 2,352m | 6.1% |
| 2023 | BRL 33,974m | +16.9% | BRL 2,080m | 6.1% |
| 2022 | BRL 29,067m | +20.5% | BRL 1,839m | 6.3% |
| 2021 | BRL 24,127m | +20.2% | BRL 1,366m | 5.7% |
| 2020 | BRL 20,067m | +14.2% | BRL 916.0m | 4.6% |
| 2019 | BRL 17,566m | +18.7% | BRL 1,118m | 6.4% |
| 2018 | BRL 14,801m | +12.0% | BRL 721.5m | 4.9% |
| 2017 | BRL 13,213m | +17.4% | BRL 792.6m | 6.0% |
| 2016 | BRL 11,257m | — | BRL 705.5m | 6.3% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of Brazilian reais, except per-share amounts.
Questions about the revenue of RD Saúde
- How much revenue did RD Saúde make in fiscal 2025?
- RD Saúde reported revenue of BRL 44,250m for fiscal 2025, compared with BRL 38,872m in fiscal 2024.
- How much has the revenue of RD Saúde grown?
- Between fiscal 2016 and fiscal 2025 it went from BRL 11,257m to BRL 44,250m: 293.1% more, an average growth of 16.4% a year.
- What was the best year for revenue at RD Saúde?
- Of its last 10 fiscal years, fiscal 2025, with BRL 44,250m.
- Where do the figures for RD Saúde come from?
- From the annual financial statements (DFP) that RD Saúde files with the CVM, the Brazilian securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual financial statements (DFP) that RD Saúde files with the CVM, the Brazilian securities regulator. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on RD Saúde: the RD Saúde page · annual accounts · net income · dividends paid.
More companies from Brazil and the rest of the region: Latin American stocks.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.